Hyperbaric oxygen therapy is used internationally for more than 80 different conditions. Research supports its use for athletic injuries and performance, arthritis, autism, attention deficit disorder, auto-immune disorders, Bell’s Palsy, brain and head injuries, burn injuries, cardiovascular disease, cerebral palsy, Crohn’s disease, dermatological conditions, diabetes, dementia, interstitial cystitis, irritable bowel syndrome and colitis, Lyme disease, learning disabilities, mild cognitive impairment, MS, neuropathies, NON-healing wounds, pervasive development disorders, post-concussion syndrome, PTSD, radiation damaged tissue, reflex sympathetic dystrophy, reconstructive surgery, stroke, transverse myelitis, TBI and more. Research is showing that it may be effective as an anti- aging and cancer prevention strategy. (link to Harch’s testimony to NIH on Utube)
HBOT is FDA approved to treat air or gas embolism, carbon monoxide and cyanide poisoning, crush injury, acute traumatic ischemia, decompression sickness, delayed radiation injury, diabetic foot ulcers, enhanced healing of problem wounds, exceptional blood loss, gas gangrene, intracranial abscess, necrotizing soft tissue infections, osteomyelitis (refractory), skin grafts and flaps (compromised), and thermal burns.
How can I learn more about HBOT?
A very comprehensive book about HBOT is The Oxygen Revolution by Paul Harch, M.D. This book is geared toward individuals who would like to learn more about how HBOT works and what conditions it treats. The book explores the science behind HBOT, as well as case histories of patients who have benefited from HBOT.
Do you take insurance?
Unfortunately, most insurance policies do not cover mild HBOT. Our fee structure for treatment and chamber sales reflects our mission, which is to make hyperbaric oxygen therapy available and accessible to those who can benefit from it.
Many of the common uses for HBOT are termed “off-label” by the FDA. What does “off-label” mean?
If a drug/device is prescribed for a particular diagnosis that does not appear on the FDA’s approved (i.e. labeled) list then its use is considered “offlabel”. Offlabel uses are neither risky nor investigational; they constitute the traditional practice of medicine that has existed long before the FDA. Often the offlabel use of a drug or medical device may, in fact, be less risky than the approved indications.
Off label use is widespread in the medical community and is often considered essential to giving patients optimal medical care. The Food and Drug Law Journal states, “Offlabel uses of medical devices and drugs perform an important therapeutic role in many, if not most, areas of medical practice”. Prescriptions for offlabel uses of drug products “may account for more than 25% of the approximately 1.6 billion prescriptions written each year, with some recent estimates running as high as 60%.” For example, Gabapentin is FDA approved for treatment of seizures and post-herpetic neuralgia in adults, but is commonly used offlabel to treat bipolar disorder, essential tremors, hot flashes, migraine, restless leg syndrome, and neuropathic pain. Beta-blockers are routinely prescribed for a variety of off-label uses, tricyclic antidepressants are prescribed for chronic pain, and antipsychotics for attention deficit hyperactivity disorder (ADHD). Pediatric uses for most medications are considered offlabel, as drugs are not routinely tested on children. Many inhaled bronchodilators, antimicrobials, anticonvulsants, and proton pump inhibitors are frequently used in children without formal FDA approval. Thus, “in some cases, if you didn’t use the drug in the offlabel way, you’d be guilty of malpractice” (Beck, J. & Azari, E., 1998). FDA, OffLabel Use, and Informed Consent: Debunking Myths and Misconceptions. Food and Drug Law Journal, 53: p. 80). Accordingly HBOT for brain injuries is simply the offlabel use of a FDA approved drug/device.
Unfortunately, certain third party payers have used the FDA label indications as a means for determining reimbursement, which, in practice, results in the untoward restriction of a physician’s ability to prescribe an approved drug/device offlabel. To be clear, the FDA label was never intended to influence the practice of medicine, but the inaccurate understanding of the FDA’s intention has been opportunistically used by third party payers to restrict reimbursement.